Early participation has provided manufacturers with rare insight into the mechanics, expectations and pressures of the process. Structured preparation and disciplined execution are increasingly critical in protecting long-term portfolio value under this new framework.

High-cost gene therapies in rare disease settings often launch with limited long-term data and significant uncertainty. Early development of payer-informed contracting frameworks can reduce risk, strengthen credibility and improve launch preparedness across markets.

When access is limited, performance matters. Establishing a repeatable framework for assessing and strengthening market access capability ensures value propositions are delivered with clarity, consistency and credibility.